{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=20",
    "query": {
      "condition": "Control Subjects",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 5448,
    "total_pages": 545,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T17:36:35.055Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03541174",
      "title": "A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Resistant Hypertension"
      ],
      "interventions": [
        {
          "name": "Aprocitentan 12.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Aprocitentan 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 730,
      "start_date": "2018-06-18",
      "completion_date": "2022-04-25",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 41,
      "location_summary": "Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03541174"
    },
    {
      "nct_id": "NCT02227290",
      "title": "Pediatric Subjects With Tinea Corporis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tinea Corporis"
      ],
      "interventions": [
        {
          "name": "Naftin Cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz North America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 230,
      "start_date": "2014-08",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Encino, California • Fremont, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227290"
    },
    {
      "nct_id": "NCT05059223",
      "title": "A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Narcolepsy",
        "Cataplexy",
        "Excessive Daytime Sleepiness"
      ],
      "interventions": [
        {
          "name": "AXS-12 (reboxetine)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axsome Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "15 Years to 75 Years"
      },
      "enrollment_count": 90,
      "start_date": "2021-09-15",
      "completion_date": "2024-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 47,
      "location_summary": "Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05059223"
    },
    {
      "nct_id": "NCT06974084",
      "title": "A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Long COVID"
      ],
      "interventions": [
        {
          "name": "Maraviroc (MVC)",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin, 10mg, 20mg, 40mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Maraviroc",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HealthBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 252,
      "start_date": "2026-07-15",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06974084"
    },
    {
      "nct_id": "NCT03234738",
      "title": "A Phase 1 Safety and PK Study of IV TP-271",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "TP-271",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tetraphase Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-08-16",
      "completion_date": "2018-01-02",
      "has_results": false,
      "last_update_posted_date": "2021-12-13",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03234738"
    },
    {
      "nct_id": "NCT01748578",
      "title": "Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "EBI-005-1",
          "type": "DRUG"
        },
        {
          "name": "EBI-005-1 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eleven Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2012-11",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-05-08",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01748578"
    },
    {
      "nct_id": "NCT07660835",
      "title": "Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate-to-Severe Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Nemolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "6 Months to 23 Months"
      },
      "enrollment_count": 35,
      "start_date": "2026-07-13",
      "completion_date": "2028-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07660835"
    },
    {
      "nct_id": "NCT00963508",
      "title": "Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediculosis"
      ],
      "interventions": [
        {
          "name": "Malathion gel 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Permethrin 1% rinse (Nix Crème)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 403,
      "start_date": "2009-08",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2014-06-13",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 7,
      "location_summary": "Hot Springs, Arkansas • Sacramento, California • Kissimmee, Florida + 4 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00963508"
    },
    {
      "nct_id": "NCT05266417",
      "title": "Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "INS-GSH",
          "type": "DRUG"
        },
        {
          "name": "Matched Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gateway Institute for Brain Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2022-02-07",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 4,
      "location_summary": "Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Davie",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05266417"
    },
    {
      "nct_id": "NCT01613040",
      "title": "A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "RO4917838",
          "type": "DRUG"
        },
        {
          "name": "RO4917838 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 169,
      "start_date": "2009-01",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-20T17:36:35.055Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01613040"
    }
  ]
}